Sanofi (SAN) Given a €80.00 Price Target by Barclays Analysts

Barclays set a €80.00 ($93.02) price objective on Sanofi (EPA:SAN) in a research note published on Thursday. The brokerage currently has a neutral rating on the stock.

Other research analysts have also issued research reports about the stock. Jefferies Financial Group set a €78.00 ($90.70) target price on shares of Sanofi and gave the stock a neutral rating in a research report on Thursday, August 16th. Credit Suisse Group set a €80.00 ($93.02) target price on shares of Sanofi and gave the stock a buy rating in a research report on Wednesday, August 1st. Deutsche Bank set a €87.00 ($101.16) target price on shares of Sanofi and gave the stock a buy rating in a research report on Monday, October 22nd. JPMorgan Chase & Co. set a €72.00 ($83.72) target price on shares of Sanofi and gave the stock a neutral rating in a research report on Tuesday, July 10th. Finally, Societe Generale set a €90.00 ($104.65) target price on shares of Sanofi and gave the stock a buy rating in a research report on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of €81.06 ($94.25).

SAN stock opened at €66.17 ($76.94) on Thursday. Sanofi has a 1 year low of €63.09 ($73.36) and a 1 year high of €92.97 ($108.10).

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: What are the risks of holding treasury bonds?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply